Cancer drugs: NPPA directs manufacturers to furnish details of landing cost

The National Pharmaceutical Pricing Authority (NPPA) has asked the manufactures to submit the details of the landing cost of the drugs imported. The ‘landing cost’ is at which a particular drug is imported in the country

cancer drugs

Recently, the NPPA had capped trade margin of 42 non-scheduled anti-cancer drugs by 30 per cent.

The National Pharmaceutical Pricing Authority (NPPA) has issued the order on March 14 directing the manufacturer to furnish the details. The manufacturers will have to submit the landing cost by March 15 with the NPPA.


Providing major relief to 22 lakh patients battling from cancer in India, the union government had capped the trade margin of the highly expensive anti-cancer drugs. With this move, the experts believe, soon, the poor and needy patients can now avail the anti-cancer drugs which are currently out of reach.

At the moment, India has over 1.5 million cancer patients, and 8 lakh people lost their lives due to cancer in 2018, due to the high cost of drugs, and the expensive cost of treatment. Many patients quit the treatment mid-way due to non-affordability of medical treatment. The government has been deliberating upon this since a time to make the drugs affordable.

Also Read :- Cancer drugs to become cheaper, NPPA caps trade margin of 42 drugs